March 21, 2024AME Case ReportsOpen Access

Effective treatment of MET exon 14 skipping mutation-positive non-small cell lung cancer using capmatinib following serious maculopapular rash caused by two MET inhibitors: a case report

View Full Paper

Ask AI

Bookmark

Abstract

Multi-gene panel testing and advancements in molecular targeted therapy have improved the overall survival of patients with driver mutation-positive non-small cell lung cancer (NSCLC). Mesenchymal-epithelial transition factor (

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kashizaki et al. (2024) studied this question.

synapsesocial.com/papers/68e7318cb6db6435876aaf68 https://doi.org/10.21037/acr-23-181

View Full Paper

Ask AI

Bookmark

Effective treatment of MET exon 14 skipping mutation-positive non-small cell lung cancer using capmatinib following serious maculopapular rash caused by two MET inhibitors: a case report

Abstract

Discussion

Cite This Study

Effective treatment of MET exon 14 skipping mutation-positive non-small cell lung cancer using capmatinib following serious maculopapular rash caused by two MET inhibitors: a case report

Abstract

Discussion

Cite This Study

Keep reading

Keep reading